Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial

• D. Rosmarin,
• S. Smith,
• D. Shrom,
• R. Burge,
• K. See,
• M. McKean‐Matthews,
• T. Ridenour,
• C.‐Y. Lin,
• J. Gorelick

Affiliations

D. Rosmarin

Tufts Medical Center Boston Massachusetts USA

S. Smith

California Dermatology and Clinical Research Institute Encinitas California USA

D. Shrom

Eli Lilly and Company Indianapolis Indiana USA

R. Burge

Eli Lilly and Company Indianapolis Indiana USA

K. See

Eli Lilly and Company Indianapolis Indiana USA

M. McKean‐Matthews

Syneos Health Morrisville North Carolina USA

T. Ridenour

Eli Lilly and Company Indianapolis Indiana USA

C.‐Y. Lin

Eli Lilly and Company Indianapolis Indiana USA

J. Gorelick

California Skin Institute San Jose California USA